Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dear Colleagues,Supramolecular systems (calixarenes, cyclodextrins, polymers, peptides, etc.) have attracted special attention due to their excellent therapeutic properties for biomedical applications such as gene and drug delivery. Numerous biomaterials-based supramolecular systems have been developed in the last decade for enhancing of biocompatibility and pharmacological activity. In particular, supramolecular nanomaterials are considered a hot research topic, because nanomedicine has become an interesting tool for the treatment of genetic diseases or cancer. Nevertheless, novel systems and their properties are being continuously studied, contributing to the development of efficient delivery systems.This Special Issue provides and highlights current progress in the use of the supramolecular systems for boosting gene and drug delivery. Preparation, characterization, and use of these systems, as well as the latest developments in this research field, are especially welcome.Authors are encorauged to submit original research articles and reviews in this promising research field.

Research & information: general --- Chemistry --- β-cyclodextrin-based nanosponge --- phenylethylamine --- 2-amino-4-(4-chlorophenyl)thiazole (AT) --- gold nanoparticles --- carrier of therapeutic agents --- ferritin --- drug delivery --- tumor targeting --- half-life extension --- PAMAM dendrimers --- folic acid --- mRNA --- gene expression --- long acting injectables --- poly(l-lactic acid) --- poly(butylene adipate) --- block copolymers --- aripiprazole --- microparticles --- sustained release --- cationic calix[4]arenes --- liposomes --- nucleic acids --- transfection efficiency --- doxorubicin --- encapsulation --- adenine–uracil base pair --- complementary hydrogen bonded drug carrier system --- controlled drug delivery --- supramolecular nanogels --- selective cytotoxicity --- supramolecular self-assembled ribbon-like structures (SRLS) --- Congo red (CR) --- doxorubicin (Dox) --- bovine serum albumin (BSA) --- immunoglobulin light chain λ (Lλ) --- heat aggregated immunoglobulins (HAI) --- dynamic light scattering (DLS) --- elution volume (Ve) --- multi-walled carbon nanotube --- photothermal therapy --- indocyanine green --- synergistic strategy --- cancer treatment --- targeted drug delivery --- pillararene --- host:guest --- supramolecular --- hydrophobic --- ITC --- NMR --- magnetoliposomes --- microfluidics --- oral drug delivery --- magnetite nanoparticles --- n/a --- adenine-uracil base pair

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dear Colleagues,Supramolecular systems (calixarenes, cyclodextrins, polymers, peptides, etc.) have attracted special attention due to their excellent therapeutic properties for biomedical applications such as gene and drug delivery. Numerous biomaterials-based supramolecular systems have been developed in the last decade for enhancing of biocompatibility and pharmacological activity. In particular, supramolecular nanomaterials are considered a hot research topic, because nanomedicine has become an interesting tool for the treatment of genetic diseases or cancer. Nevertheless, novel systems and their properties are being continuously studied, contributing to the development of efficient delivery systems.This Special Issue provides and highlights current progress in the use of the supramolecular systems for boosting gene and drug delivery. Preparation, characterization, and use of these systems, as well as the latest developments in this research field, are especially welcome.Authors are encorauged to submit original research articles and reviews in this promising research field.

Research & information: general --- Chemistry --- β-cyclodextrin-based nanosponge --- phenylethylamine --- 2-amino-4-(4-chlorophenyl)thiazole (AT) --- gold nanoparticles --- carrier of therapeutic agents --- ferritin --- drug delivery --- tumor targeting --- half-life extension --- PAMAM dendrimers --- folic acid --- mRNA --- gene expression --- long acting injectables --- poly(l-lactic acid) --- poly(butylene adipate) --- block copolymers --- aripiprazole --- microparticles --- sustained release --- cationic calix[4]arenes --- liposomes --- nucleic acids --- transfection efficiency --- doxorubicin --- encapsulation --- adenine-uracil base pair --- complementary hydrogen bonded drug carrier system --- controlled drug delivery --- supramolecular nanogels --- selective cytotoxicity --- supramolecular self-assembled ribbon-like structures (SRLS) --- Congo red (CR) --- doxorubicin (Dox) --- bovine serum albumin (BSA) --- immunoglobulin light chain λ (Lλ) --- heat aggregated immunoglobulins (HAI) --- dynamic light scattering (DLS) --- elution volume (Ve) --- multi-walled carbon nanotube --- photothermal therapy --- indocyanine green --- synergistic strategy --- cancer treatment --- targeted drug delivery --- pillararene --- host:guest --- supramolecular --- hydrophobic --- ITC --- NMR --- magnetoliposomes --- microfluidics --- oral drug delivery --- magnetite nanoparticles --- β-cyclodextrin-based nanosponge --- phenylethylamine --- 2-amino-4-(4-chlorophenyl)thiazole (AT) --- gold nanoparticles --- carrier of therapeutic agents --- ferritin --- drug delivery --- tumor targeting --- half-life extension --- PAMAM dendrimers --- folic acid --- mRNA --- gene expression --- long acting injectables --- poly(l-lactic acid) --- poly(butylene adipate) --- block copolymers --- aripiprazole --- microparticles --- sustained release --- cationic calix[4]arenes --- liposomes --- nucleic acids --- transfection efficiency --- doxorubicin --- encapsulation --- adenine-uracil base pair --- complementary hydrogen bonded drug carrier system --- controlled drug delivery --- supramolecular nanogels --- selective cytotoxicity --- supramolecular self-assembled ribbon-like structures (SRLS) --- Congo red (CR) --- doxorubicin (Dox) --- bovine serum albumin (BSA) --- immunoglobulin light chain λ (Lλ) --- heat aggregated immunoglobulins (HAI) --- dynamic light scattering (DLS) --- elution volume (Ve) --- multi-walled carbon nanotube --- photothermal therapy --- indocyanine green --- synergistic strategy --- cancer treatment --- targeted drug delivery --- pillararene --- host:guest --- supramolecular --- hydrophobic --- ITC --- NMR --- magnetoliposomes --- microfluidics --- oral drug delivery --- magnetite nanoparticles

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field.

Medicine --- Pharmaceutical industries --- bioequivalence --- Biopharmaceutics Classification System --- in vitro --- dissolution test --- pravastatin --- oral absorption --- in silico modeling --- GastroPlus --- Phoenix WinNonlin --- pharmacokinetics --- clinical studies --- ibuprofen --- manometry --- gastrointestinal --- mechanistic modeling --- PBPK --- PBBM --- disintegration --- dissolution --- enteric-coated --- ICH --- quality control --- regional intestinal permeability --- permeation enhancers --- absorption-modifying excipients --- oral peptide delivery --- intestinal perfusion --- pharmaceutical development --- controlled release drug product --- biopharmaceutics classification system --- drug solubility --- drug permeability --- location-dependent absorption --- segregated flow intestinal model (SFM) --- traditional model (TM) --- route-dependent intestinal metabolism --- first-pass effect --- drug-drug interactions --- DDI --- in vitro in vivo extrapolations --- IVIVE --- zero-order absorption --- first-order absorption --- combined zero- and first-order absorption --- transit compartment absorption model --- in situ perfusion --- microdevices --- shape --- mucoadhesion --- colon absorption --- nutrient digestion --- nutrient absorption --- gastrointestinal hormone --- postprandial glycaemia --- energy intake --- region of the gut --- obesity --- type 2 diabetes --- Franz–PAMPA --- BCS drugs --- biomimetic membrane --- Franz cell --- passive drug transport --- BCS class IV drugs --- segmental-dependent intestinal permeability --- intestinal absorption --- oral drug delivery --- biopharmaceutics --- physiologically-based pharmacokinetic (PBPK) modeling --- furosemide --- intestinal permeability --- human colon carcinoma cell layer (Caco-2) --- hierarchical support vector regression (HSVR) --- drug absorption --- drug solubility/dissolution --- regional/segmental-dependent permeability and absorption --- bioequivalence --- Biopharmaceutics Classification System --- in vitro --- dissolution test --- pravastatin --- oral absorption --- in silico modeling --- GastroPlus --- Phoenix WinNonlin --- pharmacokinetics --- clinical studies --- ibuprofen --- manometry --- gastrointestinal --- mechanistic modeling --- PBPK --- PBBM --- disintegration --- dissolution --- enteric-coated --- ICH --- quality control --- regional intestinal permeability --- permeation enhancers --- absorption-modifying excipients --- oral peptide delivery --- intestinal perfusion --- pharmaceutical development --- controlled release drug product --- biopharmaceutics classification system --- drug solubility --- drug permeability --- location-dependent absorption --- segregated flow intestinal model (SFM) --- traditional model (TM) --- route-dependent intestinal metabolism --- first-pass effect --- drug-drug interactions --- DDI --- in vitro in vivo extrapolations --- IVIVE --- zero-order absorption --- first-order absorption --- combined zero- and first-order absorption --- transit compartment absorption model --- in situ perfusion --- microdevices --- shape --- mucoadhesion --- colon absorption --- nutrient digestion --- nutrient absorption --- gastrointestinal hormone --- postprandial glycaemia --- energy intake --- region of the gut --- obesity --- type 2 diabetes --- Franz–PAMPA --- BCS drugs --- biomimetic membrane --- Franz cell --- passive drug transport --- BCS class IV drugs --- segmental-dependent intestinal permeability --- intestinal absorption --- oral drug delivery --- biopharmaceutics --- physiologically-based pharmacokinetic (PBPK) modeling --- furosemide --- intestinal permeability --- human colon carcinoma cell layer (Caco-2) --- hierarchical support vector regression (HSVR) --- drug absorption --- drug solubility/dissolution --- regional/segmental-dependent permeability and absorption

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area.

Technology: general issues --- nanostructured lipid carriers (NLC) --- formulation optimization --- rivastigmine --- quality by design (QbD) --- nasal route --- nose-to-brain --- N-alkylisatin --- liposome --- urokinase plasminogen activator --- PAI-2 --- SerpinB2 --- breast cancer --- liposomes --- target delivery nanosystem --- FZD10 protein --- colon cancer therapy --- supersaturation --- silica-lipid hybrid --- spray drying --- lipolysis --- lipid-based formulation --- fenofibrate --- mesoporous silica --- oral drug delivery --- hyaluronic acid --- drug release --- light activation --- stability --- mobility --- biocorona --- dissolution enhancement --- phospholipids --- solid dosage forms --- porous microparticles --- nanoemulsion(s) --- phase-behavior --- DoE --- D-optimal design --- vegetable oils --- non-ionic surfactants --- efavirenz --- flaxseed oil --- nanostructured lipid carriers --- nanocarrier --- docohexaenoic acid --- neuroprotection --- neuroinflammation --- fluconazole --- Box‒Behnken design --- nanotransfersome --- ulcer index --- zone of inhibition --- rheological behavior --- ex vivo permeation --- nanomedicine --- cancer --- doxorubicin --- melanoma --- drug delivery --- ultrasound contrast agents --- phospholipid coating --- ligand distribution --- cholesterol --- acoustic response --- microbubble --- lipid phase --- dialysis --- ammonia --- intoxication --- cyanocobalamin --- vitamin B12 --- atopic dermatitis --- psoriasis --- transferosomes --- lipid vesicles --- skin topical delivery --- oligonucleotide --- self-emulsifying drug delivery systems --- hydrophobic ion pairing --- intestinal permeation enhancers --- Caco-2 monolayer --- clarithromycin --- solid lipid nanoparticles --- optimization --- permeation --- pharmacokinetics --- follicular targeting --- dexamethasone --- alopecia areata --- lipomers --- lipid polymer hybrid nanocapsules --- biodistribution --- skin --- ethyl cellulose --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field.

bioequivalence --- Biopharmaceutics Classification System --- in vitro --- dissolution test --- pravastatin --- oral absorption --- in silico modeling --- GastroPlus --- Phoenix WinNonlin --- pharmacokinetics --- clinical studies --- ibuprofen --- manometry --- gastrointestinal --- mechanistic modeling --- PBPK --- PBBM --- disintegration --- dissolution --- enteric-coated --- ICH --- quality control --- regional intestinal permeability --- permeation enhancers --- absorption-modifying excipients --- oral peptide delivery --- intestinal perfusion --- pharmaceutical development --- controlled release drug product --- biopharmaceutics classification system --- drug solubility --- drug permeability --- location-dependent absorption --- segregated flow intestinal model (SFM) --- traditional model (TM) --- route-dependent intestinal metabolism --- first-pass effect --- drug-drug interactions --- DDI --- in vitro in vivo extrapolations --- IVIVE --- zero-order absorption --- first-order absorption --- combined zero- and first-order absorption --- transit compartment absorption model --- in situ perfusion --- microdevices --- shape --- mucoadhesion --- colon absorption --- nutrient digestion --- nutrient absorption --- gastrointestinal hormone --- postprandial glycaemia --- energy intake --- region of the gut --- obesity --- type 2 diabetes --- Franz–PAMPA --- BCS drugs --- biomimetic membrane --- Franz cell --- passive drug transport --- BCS class IV drugs --- segmental-dependent intestinal permeability --- intestinal absorption --- oral drug delivery --- biopharmaceutics --- physiologically-based pharmacokinetic (PBPK) modeling --- furosemide --- intestinal permeability --- human colon carcinoma cell layer (Caco-2) --- hierarchical support vector regression (HSVR) --- drug absorption --- drug solubility/dissolution --- regional/segmental-dependent permeability and absorption